<DOC>
	<DOCNO>NCT02951819</DOCNO>
	<brief_summary>The purpose study evaluate complete response plus ( + ) good partial response ( CR+VGPR ) rate follow 4 cycle induction therapy daratumumab combination cyclophosphamide , bortezomib , dexamethasone ( Dara-CyBorD ) , previously untreated subject , relapse subject multiple myeloma , define International Myeloma Working Group ( IMWG ) criterion .</brief_summary>
	<brief_title>A Study Evaluate Dara-CyBorD Previously Untreated Relapsed Subjects With Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Daratumumab</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Subjects document multiple myeloma ( MM ) define International Myeloma Working Group ( IMWG ) 2015 criterion : Clonal bone marrow plasma cell great equal ( &gt; = ) 10 percent ( % ) biopsyproven bony extramedullary plasmacytoma one follow CRAB ( calcium level , renal dysfunction , anemia , destructive bone lesion ) feature myeloma define event protocol Subjects previously untreated myeloma relapse myeloma one prior line therapy include induction regimen may follow autologous stem cell transplantation single agent maintenance therapy . For previously untreated subject emergency course steroid ( define great 40 milligram ( mg ) dexamethasone , equivalent per day maximum 4 day ) permit . In addition , radiation therapy permit prior study entry , screening , Cycles 12 study treatment need lytic bone disease Have Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 , 1 , 2 A woman childbearing potential must 2 negative serum ( beta ( Î² ) human chorionic gonadotropin ) urine pregnancy test screen , first one within 28 day prior first dose study drug second within 24 hour prior first dose study drug A man sexually active woman childbearing potential vasectomy must agree use barrier method birth control example , either condom spermicidal foam/gel/film/cream/suppository partner occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/suppository , men must also donate sperm study 3 month receive last dose study drug Refractory proteasome inhibitor ( PI ) combination PI immunomodulatory drug ( IMiD ) agent ( lenalidomide ) , defined failure respond progression within 60 day end PI therapy Exhibiting clinical sign know history meningeal central nervous system involvement multiple myeloma Has know chronic obstructive pulmonary disease force expiratory volume 1 second ( FEV1 ) less ( &lt; ) 50 percent ( % ) predict normal Has know moderate severe persistent asthma within past 2 year , currently uncontrolled asthma classification Is know seropositive human immunodeficiency virus , know hepatitis B surface antigen positivity , know history hepatitis C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>